{"id":61724,"date":"2024-03-06T08:17:36","date_gmt":"2024-03-06T08:17:36","guid":{"rendered":"https:\/\/medsname.com\/taficita\/"},"modified":"2026-05-14T05:13:54","modified_gmt":"2026-05-14T05:13:54","slug":"taficita","status":"publish","type":"product","link":"https:\/\/medsbase.com\/sv\/product\/taficita\/","title":{"rendered":"Taficita"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Taficita?<\/h3>\n<p style=\"margin:0;\"><strong>Taficita<\/strong> inneh\u00e5ller <strong>tenofovir alafenamide 25 mg + emtricitabine 200 mg<\/strong> and is used for HIV pre-exposure prophylaxis (PrEP) in HIV-negative MSM and transgender women at substantial risk. TAF-based PrEP is approved for HIV prevention in <strong>cisgender men who have sex with men (MSM) and transgender women<\/strong> (DISCOVER trial, 2019) &mdash; not for cisgender women, where trial evidence is insufficient. Daily dosing only; non-inferior to TDF\/FTC with substantially better renal and bone safety (DISCOVER trial). Manufactured by Emcure Pharmaceuticals. Specialist-supervised; requires HIV-negative status confirmed before starting and every 3 months on therapy.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f6f7fb;border:1px solid #e3e5ee;border-radius:8px;padding:14px 18px;margin:18px 0;font-size:14px;line-height:1.55;\"><strong>Vad du f\u00e5r med MedsBase:<\/strong> H\u00e4rstammar fr\u00e5n en WHO-GMP-certifierad tillverkare \u00b7 Diskret f\u00f6rpackning \u00b7 V\u00e4rldsvid leverans \u00b7 <a href=\"\/sv\/reviews\/\" rel=\"noopener\">1 400+ verifierade kundrecensioner<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Varje best\u00e4llning omfattas av v\u00e5r <a href=\"https:\/\/medsbase.com\/sv\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 om din f\u00f6rs\u00e4ndelse inte anl\u00e4nder inom 20 arbetsdagar, skickar vi om den.<\/p>\n<h3>Varf\u00f6r best\u00e4lla fr\u00e5n MedsBase<\/h3>\n<p>Att best\u00e4lla fr\u00e5n MedsBase ger dig produkter fr\u00e5n en WHO-GMP-certifierad tillverkare, diskret f\u00f6rpackning i vanliga kuvert, v\u00e4rldsomsp\u00e4nnande leverans och 4.9\u2605 betyg fr\u00e5n \u00f6ver 1 400 verifierade kunder. Kortbetalningar hanteras via en reglerad krypto-p\u00e5fart \u2014 kontoutdraget kommer att visa processorns namn (en reglerad kortbetalningsprocessor), aldrig \u201cMedsBase\u201d eller n\u00e5got l\u00e4kemedelsnamn. Varje f\u00f6rs\u00e4ndelse t\u00e4cks av v\u00e5r <a href=\"\/sv\/medsbase-re-shipment-assurance-policy\/\" rel=\"noopener\">Reshipment Assurance Policy<\/a>.<\/p>\n<p><strong>Taficita<\/strong> \u00e4r en <strong>daglig HIV-preexpositionsprofylax (PrEP)<\/strong> tablett som kombinerar <strong>tenofovir alafenamide (TAF) 25 mg<\/strong> och <strong>emtricitabine (FTC) 200 mg<\/strong> &mdash; the same fixed-dose combination that makes up the brand-name Descovy&reg; originally developed by Gilead Sciences. Taficita is Emcure Pharmaceuticals&#8217; tenofovir alafenamide + emtricitabine tablet &mdash; a Descovy-generic positioned for HIV-negative MSM and transgender women who want PrEP with the improved renal and bone safety profile of the TAF prodrug over the older TDF-based combinations.<\/p>\n<p>TAF is a <strong>newer prodrug form of tenofovir<\/strong> developed specifically to solve the renal and bone side effects of the older tenofovir disoproxil fumarate (TDF). By delivering tenofovir selectively to target cells, TAF achieves equivalent antiviral activity at approximately one-tenth the plasma tenofovir exposure &mdash; meaning much lower kidney and bone toxicity over years of daily use.<\/p>\n<h2 class=\"wp-block-heading\">What Is Taficita?<\/h2>\n<p>Taficita is a fixed-dose combination tablet of two nucleoside\/nucleotide reverse transcriptase inhibitors:<\/p>\n<ul>\n<li><strong>Tenofovir alafenamide (TAF) 25 mg<\/strong> &mdash; a prodrug of tenofovir that is activated primarily inside target cells (HIV-infected or HIV-susceptible cells). Delivers equivalent intracellular drug levels to TDF while keeping plasma tenofovir ~90% lower<\/li>\n<li><strong>Emtricitabin (FTC) 200 mg<\/strong> &mdash; the same cytidine analogue reverse transcriptase inhibitor used in TDF\/FTC regimens, with a complementary resistance profile to TAF<\/li>\n<\/ul>\n<p>Used as PrEP, Taficita pre-loads HIV-susceptible cells with reverse-transcriptase inhibitor so that any incoming virus from a sexual exposure cannot complete its reverse transcription step and therefore cannot establish chronic infection.<\/p>\n<p><strong>Klinisk ekvivalens:<\/strong> Taficita and branded Descovy contain identical active ingredients (TAF 25 mg + FTC 200 mg) and are manufactured to bioequivalence standards set by drug-regulatory bodies. The clinical evidence from DISCOVER (the TAF\/FTC PrEP trial) applies equally to all manufacturers of this fixed-dose combination.<\/p>\n<h2 class=\"wp-block-heading\">TAF vs TDF &mdash; Why Would I Choose This?<\/h2>\n<table>\n<thead>\n<tr>\n<th>\u00d6verv\u00e4gande<\/th>\n<th>TAF\/FTC (this product)<\/th>\n<th>TDF\/FTC (<a href=\"\/sv\/tenvir-em\/\" rel=\"noopener\">Tenvir EM<\/a>, etc.)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Renal safety<\/strong><\/td>\n<td>Significantly better &mdash; ~90% lower plasma tenofovir exposure. Preferred for eGFR 30&ndash;59 mL\/min (where TDF is contraindicated)<\/td>\n<td>Small decline in eGFR with long-term use; contraindicated below eGFR 60 mL\/min<\/td>\n<\/tr>\n<tr>\n<td><strong>Bone mineral density<\/strong><\/td>\n<td>Clinically meaningful advantage &mdash; no significant BMD decline observed in DISCOVER. Preferred for osteopenia\/osteoporosis<\/td>\n<td>Small but real BMD decline, particularly in the first 2 years<\/td>\n<\/tr>\n<tr>\n<td><strong>Approved PrEP populations<\/strong><\/td>\n<td><strong>Cisgender MSM and transgender women only<\/strong> (based on DISCOVER trial design). Not FDA-approved for cisgender women &mdash; trial did not include them<\/td>\n<td>All at-risk populations &mdash; cis-men, cis-women, trans people, injection drug users (iPrEx, PROUD, Partners PrEP, HPTN 084)<\/td>\n<\/tr>\n<tr>\n<td><strong>Dosing schedules<\/strong><\/td>\n<td>Daily only. On-demand 2-1-1 is <strong>not validated<\/strong> for TAF<\/td>\n<td>Daily, or on-demand 2-1-1 for cis-MSM (IPERGAY protocol)<\/td>\n<\/tr>\n<tr>\n<td><strong>Kostnad<\/strong><\/td>\n<td>Typically higher than TDF\/FTC generics<\/td>\n<td>Lowest-cost PrEP option<\/td>\n<\/tr>\n<tr>\n<td><strong>Viktf\u00f6r\u00e4ndringar<\/strong><\/td>\n<td>Small weight gain observed (~1&ndash;2 kg over a year; mechanism not fully understood)<\/td>\n<td>Weight-neutral or slight weight loss<\/td>\n<\/tr>\n<tr>\n<td><strong>Lipidprofil<\/strong><\/td>\n<td>Modestly raises LDL and total cholesterol<\/td>\n<td>Mildly lowers LDL (via TDF&#8217;s independent lipid effect)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Decision rule of thumb:<\/strong> if you have normal renal function, no bone-density concerns, and you want the widest approved indication set (and lowest cost), TDF\/FTC (<a href=\"\/sv\/tenvir-em\/\" rel=\"noopener\">Tenvir EM<\/a>) is first-line. If you have reduced eGFR (30&ndash;59), existing osteopenia\/osteoporosis, or are a cis-MSM or transgender woman wanting the safer long-term profile, Taficita is the better fit.<\/p>\n<h2 class=\"wp-block-heading\">How Taficita Works as PrEP<\/h2>\n<p>Once swallowed, TAF is stable in plasma (unlike TDF which is cleaved in blood to tenofovir) and is taken up selectively by lymphocytes, gut mucosa, and other HIV-target cells. Inside these cells, TAF is converted by cellular enzymes to the active metabolite tenofovir diphosphate, which competes with natural nucleotides at HIV reverse transcriptase and terminates DNA chain elongation.<\/p>\n<p>Key pharmacokinetic points affecting protection:<\/p>\n<ul>\n<li><strong>Koncentration i rektal v\u00e4vnad<\/strong> reaches protective levels quickly on daily dosing &mdash; DISCOVER&#8217;s exposure data showed robust protection in MSM taking &ge;4 doses per week<\/li>\n<li><strong>Cervicovaginal and injection exposure<\/strong> &mdash; TAF\/FTC is <strong>INTE godk\u00e4nd av FDA<\/strong> for cisgender women. The DISCOVER trial design did not include cis-women, so efficacy for vaginal sex and injection-drug exposure has not been formally demonstrated. Cis-women seeking PrEP should use TDF\/FTC (which has strong Partners PrEP and HPTN 084 data)<\/li>\n<li><strong>Tenofovir diphosphate (intracellular) half-life<\/strong> is long enough to tolerate an occasional missed dose, but skipping multiple doses per week meaningfully reduces protection<\/li>\n<li><strong>Skydd efter avslutad exponering<\/strong> after last exposure: continue dosing for at least 28 days after the last potential HIV exposure to cover the incubation window<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Innan du b\u00f6rjar PrEP \u2014 obligatoriska tester<\/h2>\n<p>The pre-start testing requirements for TAF\/FTC PrEP are identical to TDF\/FTC:<\/p>\n<table>\n<thead>\n<tr>\n<th>Test<\/th>\n<th>Varf\u00f6r det \u00e4r viktigt<\/th>\n<th>Tidpunkt<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>HIV-test (4:e generationens antigen\/antikropp eller HIV RNA)<\/strong><\/td>\n<td>Must be confirmed negative. Starting PrEP while unknowingly HIV-positive drives resistance (M184V, K65R) that compromises future HIV treatment options<\/td>\n<td>Inom 7 dagar efter start<\/td>\n<\/tr>\n<tr>\n<td><strong>Hepatit B ytantigen (HBsAg)<\/strong><\/td>\n<td>TAF\/FTC also treats HBV. In HBV-positive patients, discontinuing PrEP can cause a severe hepatitis flare &mdash; manage with hepatology input<\/td>\n<td>Baslinje<\/td>\n<\/tr>\n<tr>\n<td><strong>Njurfunktion (kreatinin, eGFR)<\/strong><\/td>\n<td>TAF is safer on kidneys than TDF, but still requires eGFR &ge;30 mL\/min. Below that, safety data are limited<\/td>\n<td>Baseline, then every 12 months (less frequent than with TDF)<\/td>\n<\/tr>\n<tr>\n<td><strong>STI-screening (syfilis, klamydia, gonorr\u00e9)<\/strong><\/td>\n<td>PrEP f\u00f6rhindrar HIV, inte andra STI:er. Baslinje + kvartalsvis screening \u00e4r standardv\u00e5rd<\/td>\n<td>Baslinje, var 3:e m\u00e5nad<\/td>\n<\/tr>\n<tr>\n<td><strong>Lipid panel (baseline for comparison)<\/strong><\/td>\n<td>TAF\/FTC modestly raises LDL and total cholesterol. Worth a baseline so any changes can be interpreted<\/td>\n<td>Baseline, then as clinically indicated<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Ongoing monitoring:<\/strong> HIV test every 3 months. STI screen every 3 months. Renal function at least annually. Lipid panel as clinically indicated. HBV status need not be re-tested if negative at baseline unless new risk factors arise.<\/p>\n<h2 class=\"wp-block-heading\">Dosering<\/h2>\n<p><strong>Daily only.<\/strong> One tablet taken at the same time each day. Unlike TDF\/FTC, <strong>the on-demand 2-1-1 (IPERGAY) protocol is NOT validated for TAF\/FTC<\/strong> &mdash; TAF&#8217;s distinct cellular pharmacokinetics were not studied in on-demand dosing trials, and there is no evidence base to support it. If you want the flexibility of on-demand dosing, use TDF\/FTC (<a href=\"\/sv\/tenvir-em\/\" rel=\"noopener\">Tenvir EM<\/a>) instead.<\/p>\n<p><strong>If you miss a dose:<\/strong> take it as soon as you remember within 24 hours. If more than 24 hours have passed, skip the missed dose and continue with the next scheduled one &mdash; do not double up.<\/p>\n<p><strong>Timing with food:<\/strong> can be taken with or without food. If nausea is a problem in the first weeks, taking with food helps.<\/p>\n<h2 class=\"wp-block-heading\">Biverkningar<\/h2>\n<p>TAF\/FTC is generally better tolerated than TDF\/FTC, especially in the first weeks. Most side effects occur in the &#8220;start-up&#8221; 2&ndash;4 weeks and resolve with continued use.<\/p>\n<table>\n<thead>\n<tr>\n<th>Allvarlighetsgrad<\/th>\n<th>Biverkning<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Common, transient<\/strong><\/td>\n<td>Mild nausea, diarrhoea, abdominal discomfort, headache. Generally milder than with TDF<\/td>\n<\/tr>\n<tr>\n<td><strong>Mindre vanligt<\/strong><\/td>\n<td>Weight gain (approximately 1&ndash;2 kg over 1 year), modestly raised LDL and total cholesterol, dizziness, insomnia, rash<\/td>\n<\/tr>\n<tr>\n<td><strong>S\u00e4llsynta men allvarliga<\/strong><\/td>\n<td>Lactic acidosis, severe liver enzyme elevation, hepatic steatosis, severe allergic reaction. Seek urgent medical attention for severe fatigue, unexplained muscle pain, persistent nausea, or jaundice<\/td>\n<\/tr>\n<tr>\n<td><strong>HBV-specific<\/strong><\/td>\n<td>Stopping TAF\/FTC abruptly in HBV-positive patients can trigger acute hepatitis flare &mdash; potentially life-threatening. HBV-positive patients on PrEP <strong>f\u00e5r inte sluta pl\u00f6tsligt<\/strong> utan hepatologins inblandning<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Compared to TDF\/FTC:<\/strong> lower renal toxicity, lower bone mineral density decline, slightly higher weight and lipid effects, similar GI tolerability, identical HBV considerations.<\/p>\n<h2 class=\"wp-block-heading\">Kontraindikationer och f\u00f6rsiktighets\u00e5tg\u00e4rder<\/h2>\n<ul>\n<li><strong>Bekr\u00e4ftad HIV-positiv status<\/strong> &mdash; TAF\/FTC is a 2-drug regimen that is sub-therapeutic for HIV treatment; using it selects for resistance mutations that compromise future treatment options<\/li>\n<li><strong>eGFR below 30 mL\/min<\/strong> &mdash; safety and efficacy data are limited; specialist input recommended<\/li>\n<li><strong>Akut hepatit<\/strong> \u2014 anv\u00e4nd med f\u00f6rsiktighet och r\u00e5dfr\u00e5ga en hepatolog<\/li>\n<li><strong>Amning<\/strong> &mdash; tenofovir is secreted in breast milk. TAF secretion is lower than TDF but risk\/benefit review with a clinician is advised<\/li>\n<li><strong>Women seeking PrEP for vaginal\/frontal sex exposure<\/strong> &mdash; use TDF\/FTC instead; TAF\/FTC does not have regulatory approval or trial data for this population<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">L\u00e4kemedelsinteraktioner<\/h2>\n<ul>\n<li><strong>Rifampin, rifabutin, carbamazepine, phenytoin, St John&#8217;s wort<\/strong> &mdash; strong inducers of the enzymes that activate TAF. <strong>Kontraindicerat<\/strong> or requires dose adjustment; consult a clinician<\/li>\n<li><strong>Nefrotoxiska l\u00e4kemedel<\/strong> (aminoglycosides, amphotericin B, cidofovir, IV pentamidine) &mdash; still worth avoiding despite TAF&#8217;s better renal profile<\/li>\n<li><strong>Didanosin (ddI)<\/strong> &mdash; avoid combining (historic co-toxicity concerns from TDF era, limited data for TAF but caution warranted)<\/li>\n<li><strong>HIV-postexpositionsprofylax (PEP) regimen<\/strong> &mdash; if PEP is needed after high-risk exposure, manage together with an HIV specialist<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">How to Take Taficita &mdash; Practical Guidance<\/h2>\n<ul>\n<li>Sv\u00e4lj tabletten hel med vatten, <strong>vid samma tid varje dag<\/strong>. Missing more than 1&ndash;2 doses per week meaningfully reduces protection<\/li>\n<li>Kan tas med eller utan mat<\/li>\n<li>If a dose is missed and remembered within 24 hours, take it as soon as remembered; otherwise skip the missed dose<\/li>\n<li>G\u00f6r <strong>inte<\/strong> stop PrEP suddenly if you are HBV-positive without clinician involvement<\/li>\n<li>Continue for at least 28 days after your last sexual exposure (2-dose tail) to cover the incubation window<\/li>\n<li>Return quarterly for HIV and STI testing; yearly for renal and lipid panel<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">F\u00f6rvaring<\/h2>\n<ul>\n<li>F\u00f6rvara under 30\u00b0C p\u00e5 en sval, torr plats<\/li>\n<li>Keep in the original bottle or blister packaging until use<\/li>\n<li>Anv\u00e4nd inte efter utg\u00e5ngsdatumet som anges p\u00e5 f\u00f6rpackningen<\/li>\n<li>H\u00e5ll utom r\u00e4ckh\u00e5ll f\u00f6r barn och husdjur<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Related PrEP Options on MedsBase<\/h2>\n<ul>\n<li><a href=\"\/sv\/tenvir-em\/\" rel=\"noopener\"><strong>Tenvir EM<\/strong><\/a> &mdash; Cipla&#8217;s TDF\/FTC (generic Truvada). Our most-referenced PrEP page. Approved for all at-risk populations including cis-women<\/li>\n<li><a href=\"\/sv\/ricovir-em\/\" rel=\"noopener\"><strong>Ricovir EM<\/strong><\/a> &mdash; Mylan\/Viatris TDF\/FTC alternative<\/li>\n<li><a href=\"\/sv\/tavin-em\/\" rel=\"noopener\"><strong>Tavin EM<\/strong><\/a> &mdash; Emcure TDF\/FTC alternative<\/li>\n<li><a href=\"\/sv\/tenof-em\/\" rel=\"noopener\"><strong>Tenof EM<\/strong><\/a> &mdash; Hetero TDF\/FTC alternative<\/li>\n<li><a href=\"\/sv\/std-protection-pack\/\" rel=\"noopener\"><strong>STD-skyddspaket<\/strong><\/a> &mdash; TDF\/FTC + doxycycline (DoxyPEP) + azithromycin stack for broader sexual-health coverage<\/li>\n<\/ul>\n<p>See also the <a href=\"\/sv\/hiv-medication\/\">HIV-medicin<\/a> och <a href=\"\/sv\/sexual-health\/\">Sexuell h\u00e4lsa<\/a> kategorier.<\/p>\n<h2 id=\"faqs\">Vanliga fr\u00e5gor<\/h2>\n<h3 class=\"wp-block-heading\">Is Taficita the same as Descovy?<\/h3>\n<p>Clinically equivalent. Taficita contains exactly the same active ingredients as Descovy&reg; (tenofovir alafenamide 25 mg + emtricitabine 200 mg) and is produced to pharmaceutical bioequivalence standards. The clinical evidence from the DISCOVER trial that supports TAF\/FTC PrEP applies to all bioequivalent generics of this fixed-dose combination.<\/p>\n<h3 class=\"wp-block-heading\">Can I use Taficita if I&#8217;m a cisgender woman?<\/h3>\n<p><strong>Not as first-line.<\/strong> TAF\/FTC is approved for PrEP only in cisgender MSM and transgender women because the DISCOVER trial did not enroll cisgender women. If you are a cisgender woman seeking PrEP, TDF\/FTC (for example <a href=\"\/sv\/tenvir-em\/\" rel=\"noopener\">Tenvir EM<\/a>) has strong evidence from Partners PrEP and HPTN 084 and is the correct first choice.<\/p>\n<h3 class=\"wp-block-heading\">How effective is Taficita compared to TDF\/FTC?<\/h3>\n<p>The DISCOVER trial (2019) showed TAF\/FTC is <strong>non-inferior<\/strong> to TDF\/FTC for HIV prevention in MSM and transgender women, with <strong>better renal and bone safety<\/strong>. Both regimens reduce HIV risk by &gt;99% with high adherence.<\/p>\n<h3 class=\"wp-block-heading\">Why would I pay more for Taficita versus a TDF generic?<\/h3>\n<p>Two main reasons: (1) significantly lower impact on kidney function and bone density, which matters if you plan to be on PrEP for many years or have existing risk factors; (2) you have baseline renal impairment (eGFR 30&ndash;59 mL\/min) where TDF is contraindicated. For otherwise healthy users without these considerations, TDF\/FTC is equally effective and cheaper.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Taficita on an &#8220;as-needed&#8221; schedule?<\/h3>\n<p><strong>Nej.<\/strong> The 2-1-1 (on-demand) protocol is <strong>not validated<\/strong> for TAF. Only daily dosing is supported by evidence. If you want on-demand dosing and you are cisgender MSM, use TDF\/FTC instead &mdash; IPERGAY and Prevenir data support 2-1-1 for TDF\/FTC.<\/p>\n<h3 class=\"wp-block-heading\">What about weight gain?<\/h3>\n<p>TAF\/FTC is associated with small weight gains in studies (~1&ndash;2 kg over a year). The mechanism isn&#8217;t fully understood. For most users this is clinically insignificant, but it is a real difference versus TDF\/FTC, which tends to be weight-neutral.<\/p>\n<h3 class=\"wp-block-heading\">Do I still need condoms?<\/h3>\n<p><strong>Ja.<\/strong> PrEP prevents HIV only. Condoms reduce the risk of other STIs (chlamydia, gonorrhoea, syphilis, herpes, HPV, mpox) and pregnancy. PrEP + condoms + quarterly STI screening + vaccinations (HPV, HepA, HepB if not immune) together form a complete sexual-health strategy.<\/p>\n<h3 class=\"wp-block-heading\">What happens if I stop Taficita?<\/h3>\n<p>If you are HIV-negative and HBV-negative, you can stop safely after a 28-day tail following your last HIV exposure. If you are HBV-positive, <strong>avbryt inte utan l\u00e4karr\u00e5dgivning<\/strong> &mdash; abrupt TAF discontinuation in chronic HBV can trigger an acute hepatitis flare.<\/p>\n<h3 class=\"wp-block-heading\">Can I switch from TDF\/FTC to Taficita?<\/h3>\n<p>Yes, and this is a common clinical decision when renal function declines, bone density concerns arise, or long-term safety is prioritised. Switching should be managed by a clinician with appropriate follow-up testing.<\/p>\n<h3 class=\"wp-block-heading\">Is Taficita available without a prescription?<\/h3>\n<p><strong>Nej.<\/strong> PrEP is a specialist-supervised regimen that requires baseline HIV-negative status confirmation, kidney-function and HBV testing, and follow-up every 3 months. Do not start PrEP without clinician confirmation of HIV-negative status and baseline safety tests.<\/p>\n<p><!-- medsbase-faq-h3-converted --><\/p>\n<p class=\"medsbase-bundle-link-2026-05-01\" data-marker=\"mb-bundle-link-prep-starter-pack\">Taficita (TAF\/FTC) covers HIV PrEP only; for the layered PrEP + bacterial-STI regimen see our <a href='\/sv\/prep-starter-pack\/'>PrEP Startpaket (Tenvir-EM + doxycyklin 100 mg)<\/a> \u2014 the established TDF\/FTC PrEP combo bundled with doxy-PEP coverage at a lower combined price.<\/p>\n<p class=\"medsbase-link-boost-2026-05-08\" data-marker=\"mb-link-boost-tenvir-em\">Individuals starting PrEP who cannot access TAF-based <a href=\"https:\/\/medsbase.com\/sv\/taficita\/\">Taficita<\/a> may consider <a href=\"https:\/\/medsbase.com\/sv\/tenvir-em\/\">Tenvir EM (tenofovir disoproxil fumarat 300 mg + emtricitabin 200 mg)<\/a> as the clinically equivalent TDF\/FTC alternative, sharing the same once-daily dosing schedule and equivalent long-term PrEP efficacy data.<\/p>\n<p class=\"medsbase-link-boost-2026-05-10\" data-marker=\"mb-link-boost-avonza\">Prescribers reviewing older TDF-based backbone options alongside <a href=\"https:\/\/medsbase.com\/sv\/taficita\/\">Taficita (tenofovir alafenamide 25 mg + emtricitabine 200 mg)<\/a> often reference <a href=\"https:\/\/medsbase.com\/sv\/avonza\/\">Avonza (TDF \/ lamivudine \/ efavirenz)<\/a> as the established prior-line benchmark when evaluating cost-accessibility in resource-limited settings.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2 id=\"related-alts\">Andra l\u00e4kemedel f\u00f6r sexuell h\u00e4lsa<\/h2>\n<ul>\n<li><a href=\"\/sv\/tenvir-em\/\">Tenvir EM (TDF\/FTC 300+200 mg)<\/a><\/li>\n<li><a href=\"\/sv\/ricovir-em\/\">Ricovir EM (TDF\/FTC 300+200 mg)<\/a><\/li>\n<li><a href=\"\/sv\/tenof-em\/\">Tenof EM (TDF\/FTC 300+200 mg)<\/a><\/li>\n<li><a href=\"\/sv\/tavin-em\/\">Tavin EM (TDF\/FTC 300+200 mg)<\/a><\/li>\n<li><a href=\"\/sv\/std-protection-pack\/\">STD-skyddspaket<\/a><\/li>\n<\/ul>\n<p style=\"font-size:13px;color:#555;margin:14px 0;font-style:italic;\"><strong>Medicinsk ansvarsfriskrivning:<\/strong> Informationen p\u00e5 denna sida \u00e4r endast av utbildningssyfte och ers\u00e4tter inte medicinsk r\u00e5dgivning. Konsultera alltid en kvalificerad l\u00e4kare innan du p\u00e5b\u00f6rjar, avslutar eller \u00e4ndrar n\u00e5gon medicinering.<\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 HIV-behandling<br \/>\n\u2705 Minskar viral belastning<br \/>\n\u2705 St\u00e4rker immunsystemet<br \/>\n\u2705 Lowers transmission risk<br \/>\n\u2705 Improves life expectancy<\/p>\n<p>Taficita contains Emtricitabine and Tenofovir.<\/p>","protected":false},"featured_media":61725,"comment_status":"closed","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3304,3338],"product_tag":[5827,5819,3339,5674,5815,5816,5354,5825,5826,5083,4920],"class_list":{"0":"post-61724","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-hiv-medication","9":"product_cat-prep-medication-pre-exposure-prophylaxis","10":"product_tag-descovy-generic","11":"product_tag-emcure-pharmaceuticals","12":"product_tag-emtricitabine","13":"product_tag-ftc","14":"product_tag-hiv-prevention","15":"product_tag-pre-exposure-prophylaxis","16":"product_tag-prep","17":"product_tag-taf","18":"product_tag-taf-ftc","19":"product_tag-taficita","20":"product_tag-tenofovir-alafenamide","22":"first","23":"instock","24":"shipping-taxable","25":"purchasable","26":"product-type-variable","27":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product\/61724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/comments?post=61724"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/media\/61725"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/media?parent=61724"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product_brand?post=61724"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product_cat?post=61724"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product_tag?post=61724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}